Heat Treated Bacterins for Emulsion Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Heat treatment of bacterins to reduce lipase activity, which breaks down emulsifiers in vaccines, leading to instability and loss of adjuvant and antigenic effects, is necessary to maintain vaccine stability and efficacy.
Innovation Solution
Heat treating bacterins to a temperature of about 35 to 80 °C for a sufficient period reduces lipase activity to 50% or less, maintaining acceptable antigenic activity and stabilizing emulsion vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If bacterins are heat treated to reduce lipase activity, then emulsion stability is improved, but antigenic activity may be reduced
Solution Approach 1:
The patent applies parameter changes by optimizing the heat treatment temperature range (35-80°C) and duration to achieve the desired reduction in lipase activity while preserving antigenic activity. This involves finding the optimal balance between thermal energy input for enzyme deactivation and maintaining the structural integrity of antigens.
Solution Approach 2:
The heat treatment is performed as a preliminary step before final vaccine formulation and storage. By pre-treating the bacterins to reduce lipase activity beforehand, the patent prevents subsequent emulsion breakdown during storage, ensuring long-term stability without compromising antigenic properties when properly optimized.
2Stability of the object's composition
If heat treatment temperature and duration are increased to reduce lipase activity, then emulsion stability is improved, but antigenic activity is reduced
Solution Approach 1:
The patent defines specific parameter ranges for heat treatment (35-80°C temperature, with optimal ranges identified through experimentation) to achieve the desired effect. This systematic parameter optimization allows precise control over the degree of lipase inactivation while maintaining antigen integrity.
Solution Approach 2:
The patent reduces lipase activity to 50% or less of original levels, which is sufficient to stabilize the emulsion without requiring complete enzyme elimination. This partial action approach maintains adequate antigenic activity while achieving the necessary stability threshold.
3Reliability
If no heat treatment is applied, then antigenic activity is preserved, but emulsion stability deteriorates due to lipase activity
Solution Approach 1:
The patent converts the harmful effect of lipase activity (emulsion breakdown) into a beneficial outcome by using controlled heat treatment to selectively reduce lipase activity while preserving antigenic properties. This transforms the stability problem into an opportunity for optimized vaccine formulation.
Solution Approach 2:
The heat treatment process acts as an intermediary step that mediates between the conflicting requirements of maintaining antigenic activity and achieving emulsion stability. By introducing this controlled thermal processing step, the patent reconciles the opposing demands of vaccine components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in stable emulsion vaccines with prolonged shelf life and preserved adjuvant and viral infectivity, ensuring effective immune responses in vaccinated animals.
Implementation Method 1
heating the bacterin to a temperature of about 35 to about 80 °C to form a heat treated bacterin
Implementation Method 2
Heat treatment of bacterins to reduce lipase activity
Data Source
AI summary
Heat treated bacterins, a method of producing heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins are disclosed.